HALLE/SAALE, Germany, 27 August 2015 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), today announced its financial results for the first six months ending 30 June 2015, prepared in accordance with German GAAP ("HGB") and, on a voluntary basis, in accordance with IFRS as endorsed by the European Union. The reports are available on the company website (http://www.probiodrug.de/investors/reports-and-presentations/).

KEY HIGHLIGHTS
Phase 2a study of novel treatment for Alzheimer's disease, the SAPHIR trial, initiated
Additional data on Glutaminyl Cyclases (QCs) in Alzheimer's disease published in Acta Neuropathologica
Data on Probiodrug's Anti-pGlu-3 Abeta monoclonal antibody presented at the 12th AD/PDTM 2015, Nice
Key patents on Glutaminyl Cyclase (QC) inhibition for the treatment of AD granted in Japan
Winner of the European Mediscience Awards 2015 for Best Technology
Funding of Alzheimer's research at Brigham and Women's Hospital, affiliated with Harvard Medical School
Cash and cash equivalents of EUR 14.8 million as of 30 June 2015
Net loss of EUR 6.2 million for the first six-month period compared with EUR 3.4 million in 2014  in line with company expectations
Annual General Meeting held in June, all resolutions proposed by Management and Supervisory Board approved
New members of the Supervisory Board with distinguished industry expertise appointed

POST PERIOD HIGHLIGHTS
There were no significant events subsequent to the reporting period.
CONFERENCE CALL
Probiodrug will host a conference call open to the public today at 15:00 Central European Time (CET); the presentation will also be posted to the website. The conference will be held in English.

###

For more information please contact:

Probiodrug                                                                                       
Dr Konrad Glund, CEO,                                                                
Email: contact@probiodrug.de                                                                

Hume Brophy
Mary Clark, Supriya Mathur, Alexia Faure
Tel: +44 203440 5653
Email: probiodrug@humebrophy.com

Notes to Editors:

About Probiodrug AG
Headquartered in Halle, Germany, Probiodrug AG is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer's disease.

Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes - the DP4 inhibitors - which provided the basis for a novel class of antidiabetics - the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions.

Today Probiodrug's aim is to become a leading company in the development of Alzheimer's disease treatments and to thereby provide a better life for Alzheimer's disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer's disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company's view, with a leading position in this field of research. www.probiodrug.de

About Alzheimer's disease
Alzheimer's disease is a neurological disorder, which is the most common form of dementia, and ultimately leads to death. Because Alzheimer's disease cannot be cured and is degenerative, the affected patients must increasingly rely on others for assistance. Today, 44 million people worldwide currently live with the condition and this number is expected to almost double by 2030 and to more than triple by 2050 to over 132 million. Alzheimer's also has an estimated, global societal cost of over $600 billion (World Alzheimer Report 2014).

Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Probiodrug AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.